JPS6410497B2 - - Google Patents
Info
- Publication number
- JPS6410497B2 JPS6410497B2 JP9206780A JP9206780A JPS6410497B2 JP S6410497 B2 JPS6410497 B2 JP S6410497B2 JP 9206780 A JP9206780 A JP 9206780A JP 9206780 A JP9206780 A JP 9206780A JP S6410497 B2 JPS6410497 B2 JP S6410497B2
- Authority
- JP
- Japan
- Prior art keywords
- eye
- component
- concentration
- eye drops
- intraocular pressure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003889 eye drop Substances 0.000 claims description 49
- 229940012356 eye drops Drugs 0.000 claims description 33
- 230000004410 intraocular pressure Effects 0.000 claims description 23
- 229960000686 benzalkonium chloride Drugs 0.000 claims description 11
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 claims description 11
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 10
- IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 3
- 229960001950 benzethonium chloride Drugs 0.000 claims description 3
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- -1 isopropylaminopropoxy Chemical group 0.000 claims description 2
- 229960004374 befunolol Drugs 0.000 description 14
- 230000000052 comparative effect Effects 0.000 description 14
- ZPQPDBIHYCBNIG-UHFFFAOYSA-N befunolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 ZPQPDBIHYCBNIG-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 239000000243 solution Substances 0.000 description 10
- 208000010412 Glaucoma Diseases 0.000 description 9
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 9
- 230000007794 irritation Effects 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000001742 aqueous humor Anatomy 0.000 description 7
- 239000002997 ophthalmic solution Substances 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 239000004372 Polyvinyl alcohol Substances 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 229920002451 polyvinyl alcohol Polymers 0.000 description 6
- 206010030043 Ocular hypertension Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 229940054534 ophthalmic solution Drugs 0.000 description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 239000006196 drop Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- QCHFTSOMWOSFHM-WPRPVWTQSA-N (+)-Pilocarpine Chemical compound C1OC(=O)[C@@H](CC)[C@H]1CC1=CN=CN1C QCHFTSOMWOSFHM-WPRPVWTQSA-N 0.000 description 3
- QCHFTSOMWOSFHM-UHFFFAOYSA-N SJ000285536 Natural products C1OC(=O)C(CC)C1CC1=CN=CN1C QCHFTSOMWOSFHM-UHFFFAOYSA-N 0.000 description 3
- 230000001077 hypotensive effect Effects 0.000 description 3
- 229960001416 pilocarpine Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 206010015946 Eye irritation Diseases 0.000 description 2
- 206010027646 Miosis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 210000004087 cornea Anatomy 0.000 description 2
- 231100000478 corneal permeability Toxicity 0.000 description 2
- 231100000013 eye irritation Toxicity 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000003547 miosis Effects 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000001179 pupillary effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- TVVTWOGRPVJKDJ-UHFFFAOYSA-N Befunolol hydrochloride Chemical compound [Cl-].CC(C)[NH2+]CC(O)COC1=CC=CC2=C1OC(C(C)=O)=C2 TVVTWOGRPVJKDJ-UHFFFAOYSA-N 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960001716 benzalkonium Drugs 0.000 description 1
- CYDRXTMLKJDRQH-UHFFFAOYSA-N benzododecinium Chemical compound CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 CYDRXTMLKJDRQH-UHFFFAOYSA-N 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000004240 ciliary body Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000004709 eyebrow Anatomy 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005070 sphincter Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
æ¬çºæã¯æ°èŠãªçŒå§èª¿æŽçšç¹çŒæ¶²ããšãã«é«çŒ
å§çãªããç·å
éã®æ²»çã«æå¹ãªçŒå§èª¿æŽçšç¹çŒ
液ã«é¢ããã
åŸæ¥ããé«çŒå§ççšãªããç·å
éçšã®çŒå§èª¿æŽ
å€ãšããŠã¯ããã«ã«ãã³ç¹çŒæ¶²ãå€çšãããŠã
ãããããããã«ã«ãã³ç¹çŒæ¶²ã¯çŒå§ãäžéãã
ãã®ã¿ãªãããç³åæ¬çŽçãšæ¯æ§äœã«äœçšããã
ã®çµæçž®ç³ã«ããæé»æã調ç¯æ§é害ãããã¯çµ
èå
è¡ãªã©ã®å¯äœçšãæããããšãç¥ãããŠã
ãããããå¯äœçšã¯ãšãã«é茞ã亀éé¢ä¿ã«åŸäº
ããŠããè
ã«ãšã€ãŠã¯äœæ¥äžããããŠé倧ãªå±éº
ãæããã®ã§ããããŸãçœå
éãæããåèã®æ£
è
ã®ã°ããã¯çž®ç³ã«ããèŠåé害ãå¢åŒ·ããããš
ã«ãªãããããã®ããšããããã«ã«ãã³ç¹çŒæ¶²ã«
ãããé«çŒå§ççšãªããç·å
éçšã®çŒå§èª¿æŽå€ã®
éçºãæãŸããŠããã
ãšãããã€ãªã³ç¹çŒæ¶²ã¯ãã®ãããªèŠæããç
ãããã®ã§ãããããã®ç¹çŒæ¶²ãçµèå
è¡ãçæ¯
éšçãããã¯ã¢ã¬ã«ã®ãŒæ§çŒçŒçµèçãªã©ã®å¯äœ
çšãæãããšãã«ã¯æ£ç³ã«ããçŒå§äžæãæãã
ãšããããããŸãçšããããŠããªãããã®ä»ã«ã
è¡šé¢éº»é
å€ãå粟ç¥å€ãªã©ãç·å
éçŒãªã©ã®çŒå§
éäžãããããè¬å€ãšããŠèšåºçã«è©Šã¿ãããŠã
ãããããããå®çšåã«ã¯ããã€ãŠããªãã
æè¿ã«ãªãβå容äœé®æå€ããã®é åã§ææèŠ
ããã¯ãããβå容äœé®æå€ã®ïŒçš®ã§åŸªç°åšçšè¬
ãšããŠè©äŸ¡ããã€ã€ããïŒâã¢ã»ãã«âïŒâïŒïŒ
âããããã·âïŒâã€ãœãããã«ã¢ãããããã
ã·ïŒãã³ãŸãã©ã³ïŒä»¥äžããããããŒã«ãšç¥ç§°ã
ãïŒãé«çŒå§çãªããç·å
éæ²»ççšã®ç¹çŒå€ãšã
ãŠãæçšã§ããããšãèŠåºãããã
ãšããã§å»è¬åã®å
·åãã¹ãåºæ¬çãªæ§è³ªãšã
ãŠæå¹æ§ãå®å
šæ§ããã³å®å®æ§ãããããããé«
çŒå§çãªããç·å
éæ²»ççšã®ç¹çŒæ¶²ã«ã€ããŠã¿ã
ãšçŒå§ã®éäžäœçšãšãã®é©åºŠãªæç¶æ§ãæããã
ããå¯äœçšããªããããªãã¡ç³å調ç¯æ©æ§ã«åœ±é¿
ãåãŒãããçŒã®å±æã«åœ±é¿ãåãŒãããã€åºæ¿
æ§ããªããããã«è£œå€ãšããŠå®å®ã§ããããšãå¿
èŠãšããããããã芳ç¹ããåèšãããããŒã«ã®
ç¹çŒæ¶²ãã¿ãŠã¿ããšãã®æå¹æ§ãå®å
šæ§ã¯å€ªæ ¹ã
ã«ããããçšåºŠå®èšŒãããŠããïŒãçŒç§èšåºå»å ±ã
第73å·»ã第ïŒå·ã35ã40é ïŒæå54幎ïŒåç
§ïŒã
ã®ã®ãæªã å®å
šãªç¹çŒæ¶²ãšããããªããã®ã§ã
ãã
ããã§æ¬çºæè
ãã¯ãããã«ãããããŒã«ã®ç¹
çŒæ¶²ã«ããªããã«ã¢ã«ã³ãŒã«ãªã©ãæ··ãããšãã
é©ç¢ºã«ããå®å
šãªç¹çŒæ¶²ãšããŠè£œå€åã§ãããšã
ãäºå®ãèŠåºããç¹é¡æ54â114820å·ïŒç¹å
¾63
â52609å·å
¬å ±ïŒã®çºæãå®æããã
ãã®åŸããã«ç 究ãéããçµæãåèšããªãã
ã«ã¢ã«ã³ãŒã«ãªã©ã«ä»£ããŠããããã·ãããã«ã¡
ãã«ã»ã«ããŒã¹ãçšãããšãã¯ãäžå±€ãããããŒ
ã«ãããé©ç¢ºã«ããå®å
šãªç¹çŒæ¶²ãšããŠè£œå€åã
ããªãã¡äœæ¿åºŠã§æå¹æ§ãçºæ®ããã€å±æåºæ¿ã
ããå°ãªããããé·æéå®å®ãªè£œå€åãå¯èœãšãª
ããšããäºå®ãèŠåºããæ¬çºæãå®æããã«ãã
ã€ãã
ããªãã¡æ¬çºæã¯ã(A)ãããããŒã«ã®çŒç§åŠç
ã«èš±å®¹ããã氎溶æ§ã®å¡©ã0.05ã4.0ïŒ
ïŒïŒ·ïŒïŒ¶
ïŒ
ã以äžåæ§ïŒã(B)å¡©åãã³ã¶ã«ã³ããŠã ãŸãã¯
å¡©åãã³ãŒãããŠã ã0.001ã0.1ïŒ
ã(C)ãããã
ã·ãããã«ã¡ãã«ã»ã«ããŒã¹ïŒHPMCã以äžå
æ§ïŒã0.01ã1.0ïŒ
å«æããŠãªãããã€ç·©è¡å€ã§
PHã5.0ã8.0ã«èª¿æŽããŠãªãçŒå§èª¿æŽçšç¹çŒæ¶²ã«
é¢ããã
æ¬çºæã¯ãããããŒã«ã«ããçŒå§éäžäœçšã¯ã
ã®çŒå
移è¡éã«äŸåãããããããŒã«ã®çŒå
移è¡
éã¯(B)æåã§ããå¡©åãã³ã¶ã«ã³ããŠã ãŸãã¯å¡©
åãã³ãŒãããŠã ããã³(C)æåã§ããHPMCã®
ååšã«ãã€ãŠããªããã«ã¢ã«ã³ãŒã«ãçšããã°ã
ããããäžå±€å€§å·Ÿã«å¢å€§ããããšããã€ãããã
ãŒã«ã®çŒå
移è¡éã¯ç¹å®ã®PHé åã§ãšãã«å¢å€§ã
ãããšãããããããããŒã«ã®ããã®çŒã«å¯Ÿãã
åºæ¿ã(B)æåããã³(C)æåã®ååšããã³åèšç¹å®
ã®PHé åã§(C)æåãšããŠããªããã«ã¢ã«ã³ãŒã«ã
çšããã°ãããããäžå±€æžåŒ±ãããããšãããã«
ãããããŒã«ã¯(B)æåããã³(C)æåã®ååšããã³
åèšç¹å®ã®PHé åã§(C)æåãšããŠããªããã«ã¢ã«
ã³ãŒã«ãçšããã°ãããããäžå±€é·æéå®å®ã§ã
ããšãããŸã€ããæ°ããªç¥èŠãèŠåºããŠå®æãã
ããã®ã§ããã
ããããŠæ¬çºæã®ç¹çŒæ¶²ã¯ãäœæ¿åºŠã®ãããã
ãŒã«ã«ãã€ãŠãå¹æçã«ç·å
éçŒãªã©ã®çŒå§éäž
äœçšã瀺ããã€å±æåºæ¿ãªã©ã®å¯äœçšããªããã
ããé·æéå®å®ã§ããããããããŒã«ã®ãããã
è¬çäœçšãæå¹ã«çºæ®ããããããšããã®ããã
ãŠããããç¹çŒæ¶²ã§ããã
æ¬çºæã®ç¹çŒæ¶²ã«ãããŠã(A)æåãšããŠçšãã
ãããããŒã«ã®çŒç§åŠçã«èš±å®¹ããã氎溶æ§ã®å¡©
ãšããŠã¯ããšãã°å¡©é
žå¡©ãã¯ãšã³é
žå¡©ãç¡«é
žå¡©ã
ãªã³é
žå¡©ããã¬ã€ã³é
žå¡©ããããŒã«é
žå¡©ãªã©ãã
ããããããããã®å¡©ã®ãã¡ã§ã¯çµæžæ§ã補å€åŸ
ã®å®å®æ§ãªã©ã®èŠ³ç¹ãããšãã«å¡©é
žå¡©ã奜ãŸã
ãã(A)æåã®æ¿åºŠã¯0.05ã4.0ïŒ
ã§ããããšãå¿
èŠã§ããããªããã¥ã0.1ã2.0ïŒ
ã奜ãŸããã(A)
æåã®æ¿åºŠãåèšç¯å²ããäœããšçŒå§éäžäœçšã
é¡èã§ãªããåèšç¯å²ããé«ããšäžçµæžãªã ãã§
ãªããå±æ麻é
äœçšãçºçŸããŠç·å
éæ²»çè¬ãšã
ãŠããŸã奜ãŸãããªãã
(B)æåã¯çŽ°èãªã©ã«ããæ±æãé²æ¢ããããã®
éåžžã®ä¿åå€ãšããŠäœçšãããšãšãã«åŸèš(C)æå
ãšãšãã«(A)æåã®è§èééæ§ãä¿é²ããŠãã®çŒå
移è¡éãå¢å€§ããããäœçšãå
ŒãããªããŠããã
ã®ã§ããããã©ãªãã·å®æ¯éŠé
žã¡ãã«ããã©ãªã
ã·å®æ¯éŠé
žãããã«ãªã©ã®ä¿åå€ã§ã¯ããã(A)æ
åã®çŒå
移è¡éã®å¢å€§äœçšãæåŸ
ã§ããªãã(B)æ
åãšããŠã¯äœæ¿åºŠã§é²è
å¹æãçºæ®ããç·è¿èã«
察ããŠæå¹ã§ãããçŒç²èã«å¯Ÿããåºæ¿æ§ãå°ã
ãªã©ã®èŠ³ç¹ãããšãã«å¡©åãã³ã¶ã«ã³ããŠã ã奜
ãŸããã(B)æåã®æ¿åºŠã¯0.001ã0.1ïŒ
ã§ããããš
ãå¿
èŠã§ããããªããã¥ã0.003ã0.01ïŒ
ã奜ãŸ
ããã(B)æåã®æ¿åºŠãåèšç¯å²ããäœããšé²è
å¹
æãå
åã§ãªããã€(A)æåã®çŒå
移è¡éãå¢å€§ã
ãäœçšã«ä¹ãããåèšç¯å²ããé«ããšå±æåºæ¿äœ
çšãªã©å¥œãŸãããªãäœçšãçºçŸããŠããã
(C)æåã¯ç¹çŒæ¶²ã«ç²æ§ãããããŠçŒå§éäžäœçš
ãæç¶ãããããã¯è§èãä¿è·ããäœçšãšãšã
ã«ãåèš(B)æåãšãšãã«(A)æåã®è§èééæ§ãä¿
é²ããŠãã®çŒå
移è¡éãå¢å€§ãããäœçšãæãã
ãã®ã§ããã(C)æåãšããŠã¯HPMCãçšããã
ãã(C)æåã®æ¿åºŠã¯0.01ã1.0ã§ããããšãå¿
èŠ
ã§ããããªããã¥ã0.1ã0.5ïŒ
ã奜ãŸããã(C)æ
åã®æ¿åºŠãåèšç¯å²ããäœããšçŒå§éäžäœçšã®æ
ç¶å¹æããã³è§èã®ä¿è·å¹æã«ä¹ãããã€(A)æå
ã®çŒå
移è¡éãå¢å€§ããäœçšã«ä¹ãããåèšç¯å²
ããé«ããšè£œå€åãå°é£ã«ãªãã ãã§ãªããç¹çŒ
æã®ããå¿å°ãããããªãã
æ¬çºæã®ç¹çŒæ¶²ã¯PH5.0ã8.0ã奜ãŸããã¯6.8ã
7.6ã«èª¿æŽãããã(A)æåã®çŒå
移è¡éã¯ããã
PHé åã§å¢å€§ãããããããã®PHé åã¯æ¶æ¶²ã®PH
ãšã»ãšãã©äžèŽããŠãããåèš(B)æåããã³(C)æ
åã®ååšãšãã®PHé åãšãçžãŸã€ãŠ(A)æåã®åºæ¿
äœçšãæžåŒ±ããããããããŠPHãåèšç¯å²ãã倧
ãããš(A)æåã®æº¶è§£æ§ãäœäžããåèšç¯å²ããå°
ãããš(A)æåã®çŒå
移è¡éãäœäžãããPH調æŽçš
ã®ç·©è¡å€ãšããŠã¯çŒç§åŠçã«èš±å®¹ããããã®ã§ã
ãã°ãšãã«å¶éãããªãããããšãã°ãªã³é
žäºæ°Ž
çŽ ã«ãªãŠã ãšãªã³é
žæ°ŽçŽ äºãããªãŠã ã®çµåãã
ããšãã«å¥œãŸãããã®ãšããŠãããããã
æ¬çºæã®ç¹çŒæ¶²ã«ã¯åèšæå以å€ã«å¡©åãããª
ãŠã ãå¡©åã«ãªãŠã ãããŠé
žãªã©ã®éåžžã®æ·»å å€
ãé
åããŠãããã
æ¬çºæã®ç¹çŒæ¶²ã¯ããšãã°é«çŒå§ç·å
éæ£è
ã«
ïŒãïŒæ»ŽçšåºŠç¹çŒãããšçŽïŒãïŒæéã§æ£åžžçŒå§
ã«ãã©ãçšåºŠã«ããããçŒå§éäžäœçšã瀺ãã
æ¬çºæã®ç¹çŒæ¶²ã®èª¿è£œæ³ã¯ãšãã«å¶éãããªã
ããããšãã°ç·©è¡å€ã®æ°Žæº¶æ¶²ã«(C)æåãæ·»å 溶解
ããã€ãã§ããã«(A)æåãš(B)æåãæ·»å 溶解ãã
ãããã溶液ã«æ°Žãå ããŠææã®æ¿åºŠã«èª¿æŽãã
ã®ã¡é€èéããããšã«ãã€ãŠèª¿è£œããããåªäœ
ã®æ°ŽãšããŠã¯éåžžæ»
è粟補氎ãçšããããã
ã€ãã«å®æœäŸããã³æ¯èŒäŸããããŠæ¬çºæã®ç¹
çŒæ¶²ã説æããã
å®æœäŸïŒããã³æ¯èŒäŸïŒãïŒ
第ïŒè¡šã«ç€ºãããåŠæ¹ã«ãããã€ãŠç¹çŒæ¶²ã調
æŽããã(A)æåã(B)æåããã³(C)æåãPH5.0ã
8.0ã®ç·©è¡æ¶²ã«æº¶è§£ããæ°Žãå ããŠåç¹çŒæ¶²ã調
補ããã第ïŒè¡šã«ãããŠBFEã¯ãããããŒã«ã®
å¡©é
žå¡©ãæå³ããã
The present invention relates to a novel ophthalmic solution for adjusting intraocular pressure, particularly to an ophthalmic solution for regulating intraocular pressure that is effective in treating ocular hypertension or glaucoma. Pilocarpine eye drops have been widely used as an intraocular pressure regulator for ocular hypertension or glaucoma. However, pilocarpine eye drops not only lower intraocular pressure, but also act on the pupillary sphincter and ciliary body, and are known to have side effects such as a feeling of darkness due to miosis, accommodative disorders, and conjunctival hyperemia. Such side effects pose an extremely serious danger to those working in transportation and traffic-related fields in particular. Furthermore, in the case of elderly patients with cataracts, miosis will aggravate visual impairment. For these reasons, it is desired to develop an intraocular pressure regulator for ocular hypertension or glaucoma that can replace pilocarpine eye drops. Epinephrine ophthalmic solutions were born out of this need, but these ophthalmic solutions also have side effects such as conjunctival congestion, eyebrow pain, and allergic blepharoconjunctivitis, and can sometimes lead to increased intraocular pressure due to mydriasis. , is not used much. In addition, surface anesthetics, psychotropic agents, and other drugs have been clinically tried as drugs for lowering intraocular pressure in patients with glaucoma, but none of these have been put into practical use. Recently, β-receptor blockers have started to be seen as promising in this field, and 2-acetyl-7-(2-acetyl-7-
It has been found that benzofuran (hydroxy-3-isopropylaminopropoxy) (hereinafter abbreviated as befunolol) is also useful as an eye drop for the treatment of ocular hypertension or glaucoma. By the way, the basic properties that medicines should have include efficacy, safety, and stability. When looking at eye drops for the treatment of ocular hypertension or glaucoma, they have the effect of lowering intraocular pressure and have a moderate sustainability effect, and have no side effects, that is, they do not affect the pupillary accommodation mechanism and do not affect the refraction of the eye. It is required that the drug does not cause any harmful effects, has no irritating properties, and is stable as a formulation. Looking at the Befunolol ophthalmic solution from this perspective, its efficacy and safety have been demonstrated to a certain extent by Taikon et al. ("Ophthalmology Clinic Report")
(Refer to Vol. 73, No. 3, pp. 35-40 (1978)), but it still cannot be called a perfect eye drop. Therefore, the present inventors first discovered the fact that by mixing polyvinyl alcohol etc. with Befunolol eye drops, it is possible to formulate a more accurate and safer eye drop.
-52609 Publication) was completed. As a result of further research, we found that when hydroxypropyl methylcellulose was used in place of polyvinyl alcohol, we were able to formulate befunolol more accurately and safely as an eye drop.
That is, they discovered that it is possible to formulate a formulation that is effective at low concentrations, causes less local irritation, and is stable for a long period of time, leading to the completion of the present invention. That is, the present invention provides (A) an ophthalmologically acceptable water-soluble salt of befunolol in an amount of 0.05 to 4.0% (W/V
%, hereinafter the same), (B) 0.001 to 0.1% of benzalkonium chloride or benzethonium chloride, (C) 0.01 to 1.0% of hydroxypropyl methyl cellulose (HPMC, hereinafter the same), and with a buffering agent.
This invention relates to an eye drop for adjusting intraocular pressure, which has a pH adjusted to 5.0 to 8.0. The present invention shows that the intraocular hypotensive effect of befunolol depends on the amount of befunolol transferred into the eye, and that the amount of befunolol transferred into the eye depends on the presence of benzalkonium chloride or benzethonium chloride as component (B) and HPMC as component (C). Therefore, the increase is much greater than when polyvinyl alcohol is used, and the amount of befunolol transferred into the eye increases particularly in a specific pH range.Furthermore, the irritation of befunolol to the human eye is due to component (B). and that befunolol is further attenuated in the presence of component (C) and in the above specific PH range than when polyvinyl alcohol is used as component (C); This was completed based on the striking new finding that, in a specific pH range, this method is more stable for a longer period of time than when polyvinyl alcohol is used as component (C). Therefore, the eye drops of the present invention effectively lower the intraocular pressure in glaucoma eyes even with low concentrations of befunolol, have no side effects such as local irritation, and are stable for a long period of time. It is an extremely excellent eye drop that can effectively exert pharmacological effects. In the eye drops of the present invention, examples of ophthalmologically acceptable water-soluble salts of befunolol used as component (A) include hydrochloride, citrate, sulfate,
Examples include phosphates, maleates, and fumarates. Among these salts, hydrochloride is particularly preferred from the viewpoint of economical efficiency and stability after formulation. The concentration of component (A) needs to be 0.05 to 4.0%, and preferably 0.1 to 2.0%. (A)
If the concentration of the component is lower than the above range, the intraocular pressure lowering effect will not be significant, and if it is higher than the above range, it will not only be uneconomical but also develop local anesthetic effect, making it less desirable as a therapeutic agent for glaucoma. Component (B) acts as a normal preservative to prevent contamination by bacteria, etc., and together with component (C) described later, it promotes the corneal permeability of component (A) and increases the amount of it transferred into the eye. It is also equipped with the following functions. Preservatives such as methyl paraoxybenzoate and propyl paraoxybenzoate cannot be expected to increase the amount of component (A) transferred into the eye. As component (B), benzalkonium chloride is particularly preferred from the viewpoints of exhibiting a preservative effect at low concentrations, being effective against Pseudomonas aeruginosa, and having little irritation to the ocular mucosa. The concentration of component (B) needs to be 0.001 to 0.1%, and preferably 0.003 to 0.01%. If the concentration of component (B) is lower than the above range, the preservative effect will not be sufficient and the effect of increasing the amount of component (A) transferred into the eye will be poor, and if it is higher than the above range, undesirable effects such as local irritation will occur. It's coming. Component (C) adds viscosity to the eye drops to maintain the intraocular pressure lowering effect or protect the cornea, and together with component (B), promotes the corneal permeability of component (A) to increase the amount of its intraocular transfer. It has the effect of increasing the HPMC is used as the component (C). The concentration of component (C) needs to be 0.01 to 1.0, and preferably 0.1 to 0.5%. If the concentration of component (C) is lower than the above range, the sustained effect of lowering intraocular pressure and the protective effect on the cornea will be poor, and if the concentration of component (A) is lower than the above range, the effect of increasing the amount of intraocular transfer of component (A) will be poor. This not only makes it difficult to apply the eye drops, but also makes it uncomfortable to insert the eye drops. The ophthalmic solution of the present invention has a pH of 5.0 to 8.0, preferably 6.8 to 8.0.
Adjusted to 7.6. (A) The amount of ingredients transferred into the eye is
Increases in the PH region. Moreover, this PH range is the PH of tear fluid.
The presence of components (B) and (C) together with this PH range attenuates the stimulatory effect of component (A). However, if the pH is higher than the above range, the solubility of component (A) will decrease, and if it is lower than the above range, the amount of component (A) transferred into the eye will decrease. The buffering agent for pH adjustment is not particularly limited as long as it is ophthalmologically acceptable; for example, a combination of potassium dihydrogen phosphate and disodium hydrogen phosphate is particularly preferred. In addition to the above-mentioned components, the eye drops of the present invention may contain conventional additives such as sodium chloride, potassium chloride, and boric acid. When the eye drops of the present invention are injected into the eyes of a patient with high intraocular pressure glaucoma, for example, 1 to 2 drops exhibit an excellent effect of lowering intraocular pressure to the extent that the intraocular pressure returns to normal in about 3 to 4 hours. The method for preparing the eye drops of the present invention is not particularly limited, but for example, component (C) is added and dissolved in an aqueous solution of a buffer, then components (A) and (B) are added and dissolved therein,
It is prepared by adding water to the resulting solution to adjust it to the desired concentration, and then sterilizing and filtering it. Sterilized purified water is usually used as the water medium. Next, the ophthalmic solution of the present invention will be explained with reference to Examples and Comparative Examples. Example 1 and Comparative Examples 1 to 4 Eye drops were prepared according to the prescriptions shown in Table 1. (A) component, (B) component and (C) component at pH5.0~
Each eye drop was prepared by dissolving in 8.0 buffer and adding water. In Table 1, BFE means befunolol hydrochloride.
ãè¡šã
å®æœäŸïŒã®ç¹çŒæ¶²ã¯ããªã³é
žäºæ°ŽçŽ ã«ãªãŠã
ïŒç¡æ°ŽïŒãšãªã³é
žæ°ŽçŽ äºãããªãŠã ïŒ12æ°Žå¡©ïŒã
æ»
è粟補氎ã«æº¶è§£ãã溶液80mlã«å¡©åãããªãŠã
ã溶解ããããã«HPMCãæ·»å ããæ¿ããæ¹æ
ããŠå®å
šã«æº¶è§£ããããã€ãã§BFEãš10ïŒ
å¡©å
ãã³ã¶ã«ã³ããŠã 溶液ãæ·»å ã溶解ãããããã
ãã溶液ã«æ»
è粟補氎ãå ããŠå
šéã100mlã«ã
ãã®ã¡é€èéããããšã«ãã€ãŠèª¿æŽãããå®æœ
äŸïŒã®ç¹çŒæ¶²ã¯é®å
容åšäžã«ä¿åããã°ãããµã³
ã©ã€ãããã¯ã¹ïŒ40ã50âãéæ¥6000ã«ãã¯ã¹ä»¥
äžïŒäžã«ïŒã«æéæŸçœ®ããŠãäœãå€åããªãã€
ãã
æ¯èŒäŸïŒã®ç¹çŒæ¶²ã¯ãHPMCã«ä»£ããŠããªã
ãã«ã¢ã«ã³ãŒã«ãçšããã»ãã¯å®æœäŸïŒãšåæ§ã®
æ¡ä»¶ã§èª¿æŽãããšãããå®æœäŸïŒãšãŸã€ããåæ§
ã®çµæã瀺ããã
æ¯èŒäŸïŒãïŒã®ç¹çŒæ¶²ã¯ãªã³é
žäºæ°ŽçŽ ã«ãªãŠã
ïŒç¡æ°ŽïŒãšãªã³é
žæ°ŽçŽ äºãããªãŠã ïŒ12æ°Žå¡©ïŒã
æ»
è粟補氎ã«æº¶è§£ãã溶液80mlã«å¡©åãããªãŠã
ã溶解ããã€ãã§BFEãš10ïŒ
å¡©åãã³ã¶ã«ã³ã
ãŠã 溶液ïŒæ¯èŒäŸïŒïŒãæ·»å ããããããã¯
BFEãšãã©ãªãã·å®æ¯éŠé
žã¡ãã«ããã³ãã©ãª
ãã·å®æ¯éŠé
žãããã«ãæ·»å ïŒæ¯èŒäŸïŒãïŒïŒ
ããçŽ60ãã«ãŠæº¶è§£ãããããããã溶液ã«æ»
è
粟補氎ãå ããŠå
šéã100mlã«ããã®ã¡ãé€è
éããããšã«ãã€ãŠèª¿è£œããã
ããããç¹çŒæ¶²ãã€ãã®è©Šéšã«äŸããã
(1) BFEã®çŒå
移è¡é
åç¹çŒæ¶²ã麻é
ããªãïŒçŸœã®ãŠãµã®ã®ç®ã«
20ÎŒç¹çŒãã20ååŸæ¿æ°Žãã·ãªã³ãžã§åŒãåº
ããæ¿æ°Žäžã®BFEæ¿åºŠã枬å®ããããããã
äžçŸ€ïŒçŸœãåèš60矜ã®ãŠãµã®ãçšããŠç¹çŒåŸïŒ
æéãïŒæéãïŒæéããã³ïŒæéã«ãããæ¿
æ°Žäžã®BFEæ¿åºŠã枬å®ãããçµæã第ïŒå³ã«
瀺ãã第ïŒå³ã«ãããæ¿æ°Žäžã®BFEæ¿åºŠã¯ïŒ
矜ã®ãŠãµã®ã®å¹³åå€ã§ããã
(2) çŒå§éäžäœçš
çŒå§èšã«ããåæéã®çŒå§ã枬å®ããç¹çŒæ¶²
ãç¹çŒããåã®çŒå§ãšã®å·®ãçŒå§éäžïŒmm
HgïŒããæ±ãããçµæã第ïŒå³ã«ç€ºãã第ïŒå³
ã«ãããçŒå§éäžïŒmmHgïŒã¯äžçŸ€ïŒçŸœã®ãŠãµ
ã®ã®å¹³åå€ã§ããã
(3) çŒã«å¯Ÿããåºæ¿äœçš
幎什22ã39æã®æ£åžžãªæ人ç·åïŒäººã®æå¿è
ã«åç¹çŒæ¶²ãïŒæ»ŽïŒçŽ35ÎŒïŒç¹çŒããåºæ¿ã®
çšåºŠã芳å¯ãããçµæã第ïŒå³ã«ç€ºãã第ïŒå³
ã«ãããåºæ¿ã®çšåºŠã¯ã€ãã®åºæºã«ãã€ãã
âïŒãŸã€ããåºæ¿ãæããªãã
ïŒïŒãããã«åºæ¿ãæããã
ïŒæ確ã«åºæ¿ãæããã
ïŒåŒ·ãåºæ¿ãæããã
第ïŒãïŒå³ããæãããªããšããBFEã®çŒå
移è¡éããã³çŒå§éäžäœçšã¯å¡©åãã³ã¶ã«ã³ããŠ
ã ããã³HPMCã®ååšã«ããå¢åŒ·ãããããšã
ããã«ããã®çŒã«å¯Ÿããåºæ¿ãå¡©åãã³ã¶ã«ã³ã
ãŠã ããã³HPMCã®ååšã«ãã€ãŠæžåŒ±ãããã
ãšããããã
å®æœäŸïŒãïŒããã³æ¯èŒäŸïŒãïŒ
ãªã³é
žäºæ°ŽçŽ ã«ãªãŠã ïŒç¡æ°ŽïŒãšãªã³é
žæ°ŽçŽ äº
ãããªãŠã ïŒ12æ°Žå¡©ïŒã®äœ¿çšéãå€ããŠç¹çŒæ¶²ã®
PHã第ïŒè¡šã«ç€ºãããšãå€æŽããã»ãã¯å®æœäŸïŒ
ãšåæ§ã«ããŠç¹çŒæ¶²ã調æŽããããªãPH8.5ã®ç¹
çŒæ¶²ïŒæ¯èŒäŸïŒïŒã¯æ²æ®¿ãçã調æŽãäžå¯èœã§ã
ã€ãã
ããããåç¹çŒæ¶²ã«ã€ããŠå®æœäŸïŒãšåæ§ã«ã
ãŠç¹çŒïŒæéåŸã®BFEã®çŒå
移è¡éïŒæ¿æ°Žäžã®
BFEæ¿åºŠïŒã調ã¹ããçµæã第ïŒè¡šã«ç€ºãã[Table] The eye drops of Example 1 were prepared by dissolving sodium chloride in 80 ml of a solution of potassium dihydrogen phosphate (anhydrous) and disodium hydrogen phosphate (12 hydrate) dissolved in sterile purified water, and adding HPMC to this solution. Add and stir vigorously to completely dissolve, then add and dissolve BFE and 10% benzalkonium chloride solution, add sterile purified water to the resulting solution to make a total volume of 100ml, and sterilize. Adjusted by. When the eye drop of Example 1 was stored in a light-shielding container, no change occurred even when it was left in a sunlight box (40-50°C, 6000 lux or more every other day) for one month. The eye drops of Comparative Example 1 were prepared under the same conditions as in Example 1 except that polyvinyl alcohol was used instead of HPMC, and the results were exactly the same as in Example 1. The eye drops of Comparative Examples 2 to 4 were prepared by dissolving sodium chloride in 80 ml of a solution of potassium dihydrogen phosphate (anhydrous) and disodium hydrogen phosphate (12 hydrate) dissolved in sterile purified water, and then adding BFE and 10% chloride. Add benzalkonium solution (Comparative Example 2) or
Addition of BFE and methyl paraoxybenzoate and propyl paraoxybenzoate (Comparative Examples 3 to 4)
The solution was dissolved at about 60°, sterilized purified water was added to the resulting solution to make a total volume of 100 ml, and the solution was sterilized and filtered. The obtained eye drops were subjected to the following test. (1) Amount of BFE transferred into the eye The eyes of three rabbits that were not anesthetized with each eye drop
A 20Ό drop was applied to the eye, and 20 minutes later, the aqueous humor was withdrawn with a syringe and the BFE concentration in the aqueous humor was measured. 1 after instillation using a total of 60 rabbits, 3 rabbits per group.
The BFE concentration in the aqueous humor was measured at 2 hours, 4 hours and 6 hours. The results are shown in Figure 1. The BFE concentration in the aqueous humor in Figure 1 is 3
This is the average value of rabbit feathers. (2) Intraocular pressure lowering effect Measure the intraocular pressure at each hour using a tonometer, and calculate the difference between the intraocular pressure before instilling the eye drops [intraocular pressure reduction (mm
Hg)] was calculated. The results are shown in Figure 2. The intraocular pressure drop (mmHg) in Figure 2 is the average value of three rabbits per group. (3) Eye irritation One drop (approximately 35 microns) of each eye drop was instilled into the eyes of six normal adult male volunteers aged 22 to 39 years old, and the degree of irritation was observed. The results are shown in Figure 3. The degree of stimulation in Figure 3 was based on the following criteria. -: I don't feel any stimulation. +: Slight irritation felt. : I feel clearly stimulated. : I feel a strong stimulation. As is clear from Figures 1 to 3, the amount of BFE transferred into the eye and the intraocular hypotensive effect are enhanced by the presence of benzalkonium chloride and HPMC;
Furthermore, it can be seen that irritation to human eyes is also attenuated by the presence of benzalkonium chloride and HPMC. Examples 2 to 4 and Comparative Examples 5 to 6 Eye drops were prepared by changing the amounts of potassium dihydrogen phosphate (anhydrous) and disodium hydrogen phosphate (decahydrate).
Example 1 except that the pH was changed as shown in Table 2.
Eye drops were prepared in the same manner as above. It should be noted that the eye drops with a pH of 8.5 (Comparative Example 6) caused precipitation and could not be adjusted. The amount of BFE transferred into the eye (in the aqueous humor) after 1 hour of instillation was carried out in the same manner as in Example 1 for each of the obtained eye drops.
BFE concentration) was investigated. The results are shown in Table 2.
ãè¡šã
第ïŒè¡šãããPHãé«ããªãã«ã€ããŠBFEã®çŒ
å
移è¡éãå¢å€§ããPHã5.0ã8.0ã®ç¯å²å
ã®ç¹çŒ
液ïŒå®æœäŸïŒãïŒïŒã®ã°ããã¯BFEã®çŒå
移è¡
éãå
åã§ããããšãããããPH5.0ããäœãç¹
çŒæ¶²ïŒæ¯èŒäŸïŒïŒã®ã°ããã¯BFEã®çŒå
移è¡é
ãå
åã§ãªãããªãPHã8.0ããé«ããªããšåè¿°
ã®ããšãç¹çŒæ¶²ã®èª¿è£œãäžå¯èœã§ããã
å®æœäŸïŒãïŒããã³æ¯èŒäŸïŒãïŒ
å¡©åãã³ã¶ã«ã³ããŠã ã®æ¿åºŠã第ïŒè¡šã«ç€ºãã
ãšãå€æŽããã»ãã¯å®æœäŸïŒãšåæ§ã«ããŠç¹çŒæ¶²
ã調補ããã
ããããåç¹çŒæ¶²ã«ã€ããŠå®æœäŸïŒãšåæ§ã«ã
ãŠç¹çŒ20ååŸã®BFEã®çŒå
移è¡éïŒæ¿æ°Žäžã®
BFEæ¿åºŠïŒã調ã¹ããçµæã第ïŒè¡šã«ç€ºãã[Table] From Table 2, the amount of BFE transferred into the eye increases as the pH increases, and in the case of eye drops with a pH within the range of 5.0 to 8.0 (Examples 2 to 4), BFE transfer into the eye It can be seen that the amount is sufficient. In the case of an eye drop with a pH lower than 5.0 (Comparative Example 5), the amount of BFE transferred into the eye was insufficient. Note that if the pH is higher than 8.0, it is impossible to prepare eye drops as described above. Examples 5 to 9 and Comparative Examples 7 to 9 Eye drops were prepared in the same manner as in Example 1, except that the concentration of benzalkonium chloride was changed as shown in Table 3. The amount of BFE transferred into the eye (in the aqueous humor) after 20 minutes of instillation was carried out in the same manner as in Example 1 for each of the obtained eye drops.
BFE concentration) was investigated. The results are shown in Table 3.
ãè¡šã
第ïŒè¡šãããå¡©åãã³ã¶ã«ã³ããŠã ã®æ¿åºŠãé«
ããªãã«ã€ããŠBFEã®çŒå
移è¡éãå¢å€§ããå¡©
åãã³ã¶ã«ã³ããŠã ã®æ¿åºŠã0.001ã0.1ïŒ
ã®ç¯å²
ã®ç¹çŒæ¶²ïŒå®æœäŸïŒãïŒïŒã®ã°ããã¯BFEã®çŒ
å
移è¡éãå
åã§ããããšãããããå¡©åãã³ã¶
ã«ã³ããŠã ã®æ¿åºŠã0.001ïŒ
ããäœãç¹çŒæ¶²ïŒæ¯
èŒäŸïŒãïŒïŒã®ã°ããã¯BFEã®çŒå
移è¡éãå
åã§ãªããäžæ¹0.1ïŒ
ããé«ãç¹çŒæ¶²ïŒæ¯èŒäŸïŒïŒ
ã®ã°ããã¯BFEã®çŒå
移è¡éããã以äžå¢å€§ã
ããã€çŒç²èã«å¯Ÿããåºæ¿ã匷ãããã®ã§å¥œãŸã
ããªãã
å®æœäŸ 10ã12
第ïŒè¡šã«ç€ºãããåŠæ¹ã«ãããã€ãŠå®æœäŸïŒãš
åæ§ã«ããŠç¹çŒæ¶²ã調補ããã[Table] Table 3 shows that as the concentration of benzalkonium chloride increases, the amount of BFE transferred into the eye increases. ) indicates that the amount of BFE transferred into the eye is sufficient. In the case of eye drops with a benzalkonium chloride concentration lower than 0.001% (Comparative Examples 7 to 8), the amount of BFE transferred into the eye is insufficient, while in the case of eye drops with a concentration of benzalkonium chloride higher than 0.1% (Comparative Example 9)
In this case, the amount of BFE transferred into the eye does not increase any further and the irritation to the ocular mucosa is too strong, which is not preferable. Examples 10-12 Eye drops were prepared in the same manner as in Example 1 according to the formulations shown in Table 4.
ãè¡šã
ããããç¹çŒæ¶²ã¯ããããããããçŒå§éäžäœ
çšã瀺ããã€çŒã«å¯Ÿããåºæ¿ãæžåŒ±ãããŠããã
ãããå®å®æ§ã«ãããããã®ã§ãã€ãã[Table] All of the obtained eye drops exhibited excellent intraocular hypotensive action and reduced eye irritation.
Moreover, it had excellent stability.
第ïŒãïŒå³ã¯ããããå®æœäŸïŒããã³æ¯èŒäŸïŒ
ãïŒã®ç¹çŒæ¶²ããŠãµã®ã®çŒã«ç¹çŒããããã«ãã
ãæ¿æ°Žäžã®BFEæ¿åºŠã®å€åããã³çŒå§ã®å€åã
瀺ãã°ã©ãã§ããã第ïŒå³ã¯å®æœäŸïŒããã³æ¯èŒ
äŸïŒãïŒã®ç¹çŒæ¶²ãããã®çŒã«ç¹çŒããããã«ã
ããåºæ¿é »åºŠã瀺ãã°ã©ãã§ããã
Figures 1 and 2 are Example 1 and Comparative Example 1, respectively.
Fig. 3 is a graph showing changes in BFE concentration in the aqueous humor and changes in intraocular pressure when the eye drops of Example 1 and Comparative Examples 1 to 4 were applied to rabbit eyes. It is a graph showing the stimulation frequency when the eye is instilled.
Claims (1)
âã€ãœãããã«ã¢ããããããã·ïŒãã³ãŸãã©ã³
ã®çŒç§åŠçã«èš±å®¹ããã氎溶æ§ã®å¡©ã0.05ã
4.0WïŒïŒ¶ïŒ ã(B)å¡©åãã³ã¶ã«ã³ããŠã ãŸãã¯å¡©
åãã³ãŒãããŠã ã0.001ã0.1WïŒïŒ¶ïŒ ã(C)ãã
ããã·ãããã«ã¡ãã«ã»ã«ããŒã¹ã0.01ã
1.0WïŒïŒ¶ïŒ å«æããŠãªãããã€ç·©è¡å€ã§PHã5.0
ã8.0ã«èª¿æŽããŠãªãçŒå§èª¿æŽçšç¹çŒæ¶²ã ïŒ (A)æåã®æ¿åºŠã0.1ã2.0WïŒïŒ¶ïŒ ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¹çŒæ¶²ã ïŒ (B)æåã®æ¿åºŠã0.003ã0.01WïŒïŒ¶ïŒ ã§ãã
ç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¹çŒæ¶²ã ïŒ (C)æåã®æ¿åºŠã0.1ã0.5WïŒïŒ¶ïŒ ã§ããç¹èš±
è«æ±ã®ç¯å²ç¬¬ïŒé èšèŒã®ç¹çŒæ¶²ã ïŒ PHã6.8ã7.6ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé èš
èŒã®ç¹çŒæ¶²ã ïŒ (A)æåãå¡©é žå¡©ã§ããç¹èš±è«æ±ã®ç¯å²ç¬¬ïŒé
èšèŒã®ç¹çŒæ¶²ã[Claims] 1 (A) 2-acetyl-7-(2-hydroxy-3
- an ophthalmologically acceptable water-soluble salt of benzofuran (isopropylaminopropoxy) from 0.05 to
4.0W/V%, (B) benzalkonium chloride or benzethonium chloride from 0.001 to 0.1W/V%, (C) hydroxypropyl methylcellulose from 0.01 to
Contains 1.0W/V% and has a pH of 5.0 with a buffer.
Eye drops for adjusting intraocular pressure adjusted to ~8.0. 2. The eye drop according to claim 1, wherein the concentration of component (A) is 0.1 to 2.0 W/V%. 3. The eye drop according to claim 1, wherein the concentration of component (B) is 0.003 to 0.01 W/V%. 4. The eye drop according to claim 1, wherein the concentration of component (C) is 0.1 to 0.5 W/V%. 5. The eye drop according to claim 1, which has a pH of 6.8 to 7.6. 6. The eye drop according to claim 1, wherein component (A) is a hydrochloride.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9206780A JPS5716817A (en) | 1980-07-05 | 1980-07-05 | Eye drop for adjusting intraocular pressure |
CA000359015A CA1141663A (en) | 1979-09-06 | 1980-08-26 | Ophthalmic solution for intraocular pressure adjustment |
DE8080105202T DE3064137D1 (en) | 1979-09-06 | 1980-09-02 | Ophthalmic solution for intraocular pressure adjustment |
EP80105202A EP0025202B1 (en) | 1979-09-06 | 1980-09-02 | Ophthalmic solution for intraocular pressure adjustment |
US06/183,756 US4382953A (en) | 1979-09-06 | 1980-09-03 | Ophthalmic solution for intraocular pressure reduction |
ES494808A ES8107021A1 (en) | 1979-09-06 | 1980-09-05 | Ophthalmic solution for intraocular pressure adjustment. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9206780A JPS5716817A (en) | 1980-07-05 | 1980-07-05 | Eye drop for adjusting intraocular pressure |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5716817A JPS5716817A (en) | 1982-01-28 |
JPS6410497B2 true JPS6410497B2 (en) | 1989-02-22 |
Family
ID=14044117
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9206780A Granted JPS5716817A (en) | 1979-09-06 | 1980-07-05 | Eye drop for adjusting intraocular pressure |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPS5716817A (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0673542B2 (en) * | 1991-01-18 | 1994-09-21 | æéäŒç€Ÿã¢ãã€ã | Deodorant aqueous solution composition |
JP2005008596A (en) * | 2003-06-20 | 2005-01-13 | Kobayashi Pharmaceut Co Ltd | Ophthalmological composition |
JP4969052B2 (en) * | 2005-03-31 | 2012-07-04 | å°æ補è¬æ ªåŒäŒç€Ÿ | Ophthalmic composition |
EP2398443A2 (en) * | 2009-02-20 | 2011-12-28 | Micro Labs Limited | Storage stable prostaglandin product |
JP5627235B2 (en) * | 2009-12-28 | 2014-11-19 | å°æ補è¬æ ªåŒäŒç€Ÿ | Ophthalmic composition |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5639013A (en) * | 1979-09-06 | 1981-04-14 | Kaken Pharmaceut Co Ltd | Ophthalmic solution for regulating intraocular tension |
-
1980
- 1980-07-05 JP JP9206780A patent/JPS5716817A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPS5716817A (en) | 1982-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100452715B1 (en) | Use of certain isoquinolinesulfonyl compounds for the treatment of glaucoma and ischemia | |
WO1993024121A1 (en) | Remedy for glaucoma | |
JPS6038323A (en) | Ophthalmic anti-inflammatory agent | |
CN114585365A (en) | Use of parasympathomimetic agents alone or in combination with one or more alpha agonists to produce multifocal patients in pseudolens patients | |
CN108883102A (en) | For treating the composition and method of farsightedness | |
EP0025202B1 (en) | Ophthalmic solution for intraocular pressure adjustment | |
US5049587A (en) | Ophthalmic solution for intraocular pressure adjustment | |
AU2020290443A1 (en) | Carabachol-bromonidine formulation to enhance anti-presbyopia effects | |
JPH03133936A (en) | Gel-like protein shaping agent for ophthalmic application | |
AU673533B2 (en) | Pharmaceutical composition | |
JPS6352609B2 (en) | ||
JPS6410497B2 (en) | ||
CA2481394A1 (en) | Drop-forming ophthalmic gel preparation comprising diclofenamide and timolol | |
EP1297849B1 (en) | Remedial agent for optic nerve diseases | |
WO2002040028A1 (en) | Antibacterial gel eye drops | |
JP2610619B2 (en) | Eye drops for the treatment of ocular hypertension | |
KR100193406B1 (en) | Composition for the prevention and treatment of myopia | |
EP0279121B1 (en) | Pharmaceutical compositions comprising an aqueous solution of a pyranoquinoline derivative | |
US4764530A (en) | Pharmaceutical compositions and their use as mydriatics | |
TW304879B (en) | ||
JPS6411004B2 (en) | ||
JPS6256130B2 (en) | ||
JPH0330571B2 (en) | ||
AU770365B2 (en) | The process for manufacturing formulation of topical beta blockers with improved efficacy | |
CN110200904B (en) | Intraocular pressure reducing sustained-release eye drop composition and preparation method thereof |